Londres, 16 maart (EFE) .- The British pharmaceutical company AstraZeneca announced this March an agreement with the United States for the sending of 500,000 additional doses of potentially contraindicated treatment, which, if authorized, could protect the viruses which can not be vacated.
In a statement, the company explained that the pact with the Department of Health and Human Services (HHS, in English) and the Department of Defense amplified another agreement in October 2020 by the EE.UU. received 100,000 initial doses of the pharmacy “AZD7442”, with the option to purchase more in 2021, and is compromised to meet the ultimate phase of clinical studies.
With the 500,000 extra doses announced and another 100,000 more agreed in parallel with Defense, AstraZeneca could sum up in Washington in 2021 has 700,000 doses of medicine, signaled at the note.
“The combination of anti-cancer effects and long-term placement has the potential to offer protection in cases where those can be evacuated, so as to prevent contact as to treat patients and contact them,” said the councilor.
“The United States Government’s support is critical to accelerating the development of AZD7442, which we believe will be an important issue in the case of covid-19”, added.
The pharmacy, which was designed to reduce the resistance of the most potent variants of the virus, is currently being evaluated in clinical trials with 9,000 volunteers in various parts of the world, the communication indicates.
AstraZeneca reports that the total value of the agreements reached with the Governor for the development and the sum of AZD7442 during 2021 ascends to 726 million dollars. EFE
jm / er / ah
| K: SOC: SOCIEDAD-SALUD, SALUD |
| V: SYS: es-ES: 07002000: Sanidad y salud: Epidemias y plagas |
| P: GBR |
03/16 / 10-27 / 21